Eli Lilly, a global healthcare company, completed the acquisition of Prevail Therapeutics, a gene therapy company, from private equity firms OrbiMed Advisors and Pontifax for $1bn. "We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and dementia," Mark Mintun, Lilly Vice President of pain and neurodegeneration research.